drugset / Trial / NCT06132945

A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain

NCT06132945

Phase 1 Active not recruiting 2 enrolled Memorial Sloan Kettering Cancer Center Exelixis · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.

Timeline

Start
2023-11-10
Primary completion
2027-11
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabozantinib Small molecule 40 mg Oral